Article on recent ratings: Average buy at US$2.66Amyris Inc. (NASDAQ:AMRS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. “
Separately, Singular Research restated a “buy” rating and issued a $2.80 price target on shares of Amyris in a research note on Wednesday, September 28th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $2.66.
Shares of Amyris (NASDAQ:AMRS) traded down 2.78% during trading on Wednesday, hitting $1.05. 22,356,959 shares of the company’s stock were exchanged. Amyris has a 1-year low of $0.31 and a 1-year high of $1.85. The stock’s market cap is $246.77 million. The stock’s 50-day moving average price is $0.57 and its 200-day moving average price is $0.59.
Amyris (NASDAQ:AMRS) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.06. The business earned $9.60 million during the quarter, compared to analyst estimates of $15.23 million. During the same quarter last year, the company posted ($0.47) earnings per share. The company’s revenue was up 23.1% on a year-over-year basis. On average, equities analysts expect that Amyris will post ($0.20) earnings per share for the current fiscal year.
In other Amyris news, major shareholder (Mauritius) Pte Ltd Maxwell sold 2,300,000 shares of the stock in a transaction dated Monday, October 17th. The shares were sold at an average price of $0.83, for a total transaction of $1,909,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 48.70% of the company’s stock.
A number of large investors have recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Amyris during the first quarter worth about $269,000. Geode Capital Management LLC increased its stake in shares of Amyris by 11.6% in the first quarter. Geode Capital Management LLC now owns 298,669 shares of the company’s stock worth $331,000 after buying an additional 30,958 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock worth $766,000 after buying an additional 311,142 shares during the last quarter. Hedge funds and other institutional investors own 35.68% of the company’s stock.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.